Lactobacillus plantarum 299v: Iron Absorption, IBS, and the Strain-Specific Trial Record

6 min read ·
Bottom Line

L. plantarum 299v has two lines of evidence behind it: a modest improvement in IBS symptoms (low-certainty, comparable to other studied probiotic strains) and a small, distinctive boost to non-heme iron absorption and iron stores when taken with iron, plus markedly better tolerance of oral iron supplements. Neither effect is dramatic, and strain selection matters — a generic L. plantarum product cannot be assumed to reproduce it. Use 299v (DSM 9843) specifically, or you are not buying the studied organism.

Probiotic marketing typically reduces to species names and CFU counts. The actual clinical evidence runs at the strain level, where small genetic differences produce meaningfully different metabolic and adherence properties. Lactobacillus plantarum 299v (catalog designation DSM 9843) is among the more extensively studied strains in probiotic research, with two reasonably developed lines of evidence: irritable bowel syndrome symptom relief, and — more unusually for a probiotic — an apparent ability to improve iron absorption and the tolerability of oral iron. Neither effect is large, and both should be read with the usual caveat that probiotic trials are heterogeneous and often industry-supported. What follows is what the trials and meta-analyses actually show.

The iron signal: real but modest

The interesting and distinctive claim for 299v is that it improves the absorption of non-heme (plant-form) iron, which is normally poorly absorbed. The most rigorous synthesis to date is a 2025 systematic review and meta-analysis of probiotic and prebiotic effects on iron status in women and children (Apte 2025). Pooling eight studies in women of reproductive age, it found low-certainty evidence that probiotics or prebiotics — with 299v and galacto-oligosaccharide singled out as the active examples — produced a small improvement in the fractional absorption of iron versus placebo or iron alone. A separate pooled analysis of six studies found a significant rise in ferritin (a measure of iron stores) of about 2.5 ng/mL. Crucially, the same review found no convincing effect on hemoglobin in either women or children. So the honest framing is: a measurable nudge to iron uptake and iron stores, not a transformation of iron status, and the certainty of the evidence is low.

The proposed mechanism is plausible chemistry rather than anything exotic: lactic-acid bacteria lower local pH and produce reductants that favor the ferrous (Fe2+) form of iron and its uptake at the intestinal brush border. A 2024 randomized trial adds a practical angle: in 295 patients with iron-deficiency anemia starting oral iron, adding 299v cut gastrointestinal intolerance (notably abdominal pain and bloating) from about 47% to 13%, roughly tripled the odds of staying on treatment, and was associated with modestly higher iron and hemoglobin gains at three months (Koker 2024). That trial was open-label and not placebo-controlled, so the tolerability finding is more persuasive than the iron-status numbers — but better tolerance is itself a real reason iron-deficient patients might benefit, since iron supplements are notorious for being abandoned over GI side effects.

The IBS evidence is more conventional

For irritable bowel syndrome, 299v has a genuine strain-level trial record. An early small double-blind trial in 40 patients reported that abdominal pain resolved in all of the 299v group versus about half of the placebo group, with overall symptom improvement in 95% versus 15% (Niedzielin 2001) — impressive figures, but from a tiny study prone to overstating effect. The larger and more reliable trial randomized 214 patients meeting Rome III criteria to 299v or placebo for four weeks and found significantly lower abdominal pain severity and frequency, and less bloating, with 78% rating the effect as good or excellent versus 8% on placebo (Ducrotté 2012).

Where 299v fits among probiotics for IBS is best judged from the large pooled analyses. A 2023 systematic review and meta-analysis of 82 trials (over 10,000 patients) found low-certainty evidence that Lactobacillus strains and specifically L. plantarum 299v benefit global IBS symptoms — while stressing that certainty across almost all probiotic analyses was low to very low (Goodoory 2023). A 2026 strain-specific meta-analysis restricted to single-strain, placebo-controlled trials likewise listed 299v among the handful of strains (alongside Bifidobacterium infantis 35624 and Lactobacillus rhamnosus GG) with demonstrable efficacy on key IBS symptoms (Maslennikov 2026). The takeaway: 299v is not dramatically more effective than other evidence-backed strains, but it sits in the small group that has the per-strain randomized data to support a recommendation at all. Most marketed probiotics carry far less.

Dosing, labeling, and safety

Trial doses commonly sit around 10 billion CFU (1 × 1010) per day, usually a single daily capsule. For the iron effect, taking it around the iron-containing meal or iron supplement is the pattern that was studied; for IBS, the trials used consistent daily dosing over weeks. Because the evidence is strain-specific, the label should name "299v" (or DSM 9843) explicitly — a generic "Lactobacillus plantarum" product is not the studied organism and cannot be assumed to behave the same way.

Safety has been good across the trial record in healthy and IBS populations, with adverse-event rates not significantly different from placebo in the large IBS meta-analyses. The standard probiotic caution applies to severely immunocompromised patients, critically ill patients, and those with central venous catheters or damaged gut barriers, where any live-organism supplement carries a small but real risk of bacteremia or fungemia. For otherwise healthy adults, 299v is low-risk; the realistic question is not safety but whether a modest, low-certainty benefit is worth the cost.

Sources

  1. Ducrotté P, Sawant P, Jayanthi V. "Clinical trial: Lactobacillus plantarum 299v (DSM 9843) improves symptoms of irritable bowel syndrome." World Journal of Gastroenterology, 2012;18(30):4012–4018. PMID 22912552. DOI: 10.3748/wjg.v18.i30.4012.
  2. Niedzielin K, Kordecki H, Birkenfeld B. "A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome." European Journal of Gastroenterology & Hepatology, 2001;13(10):1143–1147. PMID 11711768. DOI: 10.1097/00042737-200110000-00004.
  3. Goodoory VC, Khasawneh M, Black CJ, Quigley EMM, Moayyedi P, Ford AC. "Efficacy of Probiotics in Irritable Bowel Syndrome: Systematic Review and Meta-analysis." Gastroenterology, 2023;165(5):1206–1218. PMID 37541528. DOI: 10.1053/j.gastro.2023.07.018.
  4. Maslennikov R, Gosteeva E, Ananeva V, Korshunova L, Kravtsowa A, Poluektova E, et al. "Strain-Specific Systematic Review with Meta-Analysis of Probiotics Efficacy in the Treatment of Irritable Bowel Syndrome." Journal of Clinical Medicine, 2026;15(3):1152. PMID 41682832. DOI: 10.3390/jcm15031152.
  5. Apte A, Parge A, Nimkar R, Sinha A. "Effect of probiotic and prebiotics supplementation on hemoglobin levels and iron absorption among women of reproductive age and children: a systematic review and meta-analysis." BMC Nutrition, 2025;11(1):31. PMID 39920867. DOI: 10.1186/s40795-025-01015-3.
  6. Koker G, Sahinturk Y, Ozcelik Koker G, Coskuner MA, Eren Durmus M, Catli MM, Cekin AH. "Improved gastrointestinal tolerance and iron status via probiotic use in iron deficiency anaemia patients initiating oral iron replacement: a randomised controlled trial." British Journal of Nutrition, 2024;132(10):1308–1316. PMID 39494607. DOI: 10.1017/S0007114524002757.

Related supplements